Frontage continues build-out to meet late-stage developers demand
The addition of 10,000 square feet in its Exton, PA, laboratory space was announced by Frontage Laboratories in October 2019. At that point, the company stated that the expansion will enable enhancement of its capabilities in biologic drugs development.
Frontage has cut the ribbon at the facility, which now totals 80,000 square feet. This brings the bioanalytical capabilities additions completed during the past four months to 52,000 square feet, in an aim to support the booming R&D business of biologics.
This conclusion comes after the establishment of a 42,000 square foot laboratory in Shanghai, China, dedicated to bioanalytical services. Apart from its bioanalytical business, Frontage also has recently invested in scaling up its facility in New Jersey, dedicated to nicotine-related studies.
Following the build-out completion, the facility in Exton is equipped with increased sample management and laboratory space, as well as enhanced instrumentation, systems, robotics automation, software and personnel capacity.
Frontage also has established a center of excellence supporting cell and gene therapies development at the location. The center includes dedicated laboratories in DNA/RNA sample preparation, polymerase chain reaction services, flow cytometry, and cell culture.
According to the company, the site now houses ‘greater’ biomarker, PK, and immunogenicity bioanalytical capacity, to support large clinical studies at Phase II-IV.
